Vitrolife 과거 수익 실적
과거 기준 확인 0/6
Vitrolife's earnings have been declining at an average annual rate of -71.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 24.9% per year.
주요 정보
-71.9%
수익 성장률
-71.3%
EPS 성장률
Biotechs 산업 성장 | 0.7% |
매출 성장률 | 24.9% |
자기자본 수익률 | -29.0% |
순이익 | -107.0% |
다음 실적 업데이트 | 30 Jan 2025 |
최근 과거 실적 업데이트
Recent updates
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Aug 21Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Jul 20Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
Jul 18Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
Apr 03A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Mar 07Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
Feb 05Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
Jan 05Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
Dec 15Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Nov 27Is Vitrolife (STO:VITR) A Risky Investment?
Nov 06An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued
Aug 25Vitrolife (STO:VITR) Could Easily Take On More Debt
Aug 03Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?
May 26Is Vitrolife (STO:VITR) A Risky Investment?
Jan 23Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
Oct 18Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Sep 09Is Vitrolife (STO:VITR) A Risky Investment?
Jul 07A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
May 26Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly
Mar 31Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Feb 07수익 및 비용 분석
Vitrolife 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 3,555 | -3,805 | 1,181 | 117 |
30 Jun 24 | 3,535 | -3,799 | 1,150 | 118 |
31 Mar 24 | 3,499 | -3,836 | 1,118 | 126 |
31 Dec 23 | 3,512 | -3,851 | 1,117 | 127 |
30 Sep 23 | 3,462 | 402 | 1,092 | 122 |
30 Jun 23 | 3,412 | 388 | 1,076 | 124 |
31 Mar 23 | 3,336 | 412 | 1,048 | 133 |
31 Dec 22 | 3,234 | 394 | 1,002 | 143 |
30 Sep 22 | 2,893 | 353 | 961 | 157 |
30 Jun 22 | 2,501 | 349 | 811 | 151 |
31 Mar 22 | 2,054 | 305 | 656 | 133 |
31 Dec 21 | 1,681 | 341 | 503 | 114 |
30 Sep 21 | 1,549 | 415 | 353 | 103 |
30 Jun 21 | 1,464 | 399 | 333 | 94 |
31 Mar 21 | 1,291 | 325 | 308 | 91 |
31 Dec 20 | 1,246 | 287 | 311 | 92 |
30 Sep 20 | 1,273 | 276 | 324 | 97 |
30 Jun 20 | 1,331 | 294 | 342 | 102 |
31 Mar 20 | 1,502 | 377 | 365 | 105 |
31 Dec 19 | 1,480 | 383 | 351 | 100 |
30 Sep 19 | 1,391 | 371 | 342 | 88 |
30 Jun 19 | 1,297 | 339 | 318 | 80 |
31 Mar 19 | 1,199 | 324 | 293 | 74 |
31 Dec 18 | 1,151 | 310 | 284 | 72 |
30 Sep 18 | 1,102 | 294 | 278 | 70 |
30 Jun 18 | 1,064 | 284 | 276 | 70 |
31 Mar 18 | 1,066 | 276 | 276 | 69 |
31 Dec 17 | 1,046 | 264 | 270 | 69 |
30 Sep 17 | 1,026 | 255 | 266 | 71 |
30 Jun 17 | 991 | 234 | 262 | 70 |
31 Mar 17 | 913 | 211 | 254 | 68 |
31 Dec 16 | 856 | 190 | 250 | 62 |
30 Sep 16 | 804 | 188 | 235 | 55 |
30 Jun 16 | 771 | 196 | 231 | 55 |
31 Mar 16 | 747 | 186 | 223 | 53 |
31 Dec 15 | 722 | 183 | 220 | 56 |
30 Sep 15 | 660 | 154 | 213 | 56 |
30 Jun 15 | 609 | 137 | 195 | 48 |
31 Mar 15 | 554 | 122 | 186 | 45 |
31 Dec 14 | 511 | 109 | 172 | 42 |
30 Sep 14 | 497 | 96 | 168 | 52 |
30 Jun 14 | 481 | 77 | 166 | 58 |
31 Mar 14 | 467 | 67 | 165 | 59 |
31 Dec 13 | 453 | 56 | 164 | 59 |
양질의 수익: VITR is currently unprofitable.
이익 마진 증가: VITR is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: VITR is unprofitable, and losses have increased over the past 5 years at a rate of 71.9% per year.
성장 가속화: Unable to compare VITR's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: VITR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
자기자본 수익률
높은 ROE: VITR has a negative Return on Equity (-28.96%), as it is currently unprofitable.